Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 15,176	$ 19,031
Prepaid expenses and other current assets	818	111
Total current assets	15,994	19,142
Property, equipment and leasehold improvements, net	140	127
Restricted cash - non-current	150	150
Operating lease right-of-use assets	1,135	1,229
Prepaid clinical trial expenses	1,122	1,122
Total assets	18,541	21,770
Current liabilities:
Accounts payable	899	605
Operating lease liabilities	370	361
Accrued expenses	808	1,646
Total current liabilities	2,077	2,612
Other liabilities	95	94
Operating lease liabilities - non-current	853	949
Total liabilities	3,025	3,655
Commitments and contingencies (Note 5)
Stockholders' equity:
Common stock, $0.00001 par value, authorized 2,000,000 shares; 1,370,595 shares issued and outstanding, including 254 shares of unvested restricted stock awards, at March 31, 2022 and December 31, 2021	3	3
Additional paid-in capital	256,297	256,241
Accumulated deficit	(240,784)	(238,129)
Total stockholders' equity	15,516	18,115
Total liabilities and stockholders' equity	$ 18,541	$ 21,770